Market size, share and growth analysis by product type, application, end user and sales channel, across all major regions and key countries, with forecasts for 2025–2034. The competitive landscape profiles 15+ companies.
The global high flow nasal cannula market was valued at USD 3.7 Bn in 2025 and is projected to reach USD 5.9 Bn by 2034, growing at a CAGR of 5.4%. Asia Pacific is the largest regional market and North America is growing fastest.
As per the current market research conducted by the CMI Team, the Global High Flow Nasal Cannula Market is expected to record a CAGR of 5.4% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 3.7 billion. By 2034, the valuation is anticipated to reach USD 5.9 billion.
Source: Custom Market Insights analysis.
To learn more about this report - request a sample report PDF
A medical device called a High Flow nasal cannula is used to enable High Flow therapy, also referred to as heated humidified High Flow therapy. Patients with respiratory disorders can receive a steady supply of medicinal gas through the cannula, which is a component of a respiratory support system.
The primary function of the High Flow nasal cannula is to facilitate the delivery of 100% oxygen and 60 liters of medicinal gas per minute. The conventional medical gas delivery system, the nasal cannula, which can provide 1-6 liters of medical gas per minute, has been partially replaced by the High Flow nasal cannula.
The medical requirements of patients with severe or life-threatening respiratory disorders can be satisfied because the apparatus supports high flow. Patients with respiratory obstruction or failure brought on by illnesses including bronchiolitis, acute exacerbations of chronic obstructive pulmonary disease (COPD), congestive heart failure, asthma, pneumonia, and a few others are usually treated with it. Due to the growing number of patients worldwide, the High Flow nasal cannula business is expanding quickly.
Growing prevalence of smoking drives market growth
One of the reasons behind the market for high-flow nasal cannulas (HFNCs) expanding dramatically is the rising frequency of smoking. Smoking is among the main risk factors for disorders like chronic obstructive pulmonary disease (COPD) and asthma. Like smoking raises the frequency of these respiratory diseases, the use of effective respiratory support devices like HFNC systems is absolutely essential.
The Global Action to End Smoking research estimates that 253.0 million Indians aged 15 and above will use tobacco products in 2022 (200.2 million men and 53.5 million women). For the total number of tobacco users, this ranks second globally and first in the WHO South-East Asia Region.
Increasing collaboration is expected to florish the industry expansion
The growing collaboration is expected to offer a lucrative opportunity for market growth during the forecast period. For instance, in March 2023, The Desert Oasis Healthcare (DOHC) system in California has adopted a respiratory patient monitoring program that uses data from Teva's Digihaler System, according to a statement released by Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
The program was created in partnership with Rimidi, a top clinical management platform that aims to improve patient experiences, streamline clinical workflows, and meet quality standards. The first and only intelligent inhaler device that can give objective data to aid patients and their physicians in better supporting asthma control is Teva's Digihaler.
High cost of equipment and subsequent treatment
A High Flow nasal cannula is expensive. The cost of a standard High Flow nasal cannula, for example, typically begins at USD 2000 and may increase depending on its features and other characteristics. Furthermore, according to a National Institutes of Health (NIH) study, the average cost of using a High Flow nasal cannula per patient in the United States was around USD 368.
Additionally, the total cost of therapy is significantly higher because it includes additional related charges like hospital stays, insurance, complementary therapies, and other extraneous expenses. The high cost of equipment and treatment in general is anticipated to limit the growth of the High Flow nasal cannula sector.
By Product Type:
The single heated tube segment is expected to dominate the market. To guarantee that the oxygen being given is both warmed and humidified, single heated tubes are essential to HFNC systems. By avoiding airway dryness and preserving mucosal integrity, this procedure greatly increases patient comfort and improves therapeutic results.
Besides, the nasal cannula segment is growing at a rapid rate. The market is driven by technological advancements, increasing prevalence of respiratory diseases, and expanding applications across various healthcare settings.
By Application:
The acute respiratory failure segment is expected to dominate the market. As a non-invasive substitute for traditional oxygen therapy and non-invasive ventilation, the High Flow nasal cannula is used as an initial support approach for ARF and post-extubation. Thus, driving the market growth.
On the other hand, the chronic obstructive pulmonary disease segment is expected to grow at the fastest rate over the forecast period due to the rising cases of COPD. Moreover, the increasing advancements in the devices florish the market growth.
Report Scope
| Feature of the Report | Details |
| Market Size in 2025 | USD 3.7 Billion |
| Projected Market Size in 2034 | USD 5.9 Billion |
| Market Size in 2024 | USD 3.5 Billion |
| CAGR Growth Rate | 5.4% CAGR |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Key Segment | By Product Type, Application, End User, Sales Channel and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
North America is projected to dominate the high flow nasal cannula market. This is because of the region's growing disease prevalence, developed infrastructure, and the strong presence of important players. In addition, a few additional factors driving market expansion in North America include expanding air pollution, an aging population, and an increasing need for fast-acting and highly effective medications.
However, the Asia Pacific is projected to capture the significant market share in 2024. This is due to the rising prevalence of smoking. Moreover, the shift towards home healthcare drives the industry expansion.
The high-flow nasal cannula industry adopted several strategies, which include product launches, acquisitions, collaboration, expansion, and others. Some of the company strategies include
The increasing collaboration and product launch are the strategies that have expanded the market presence of the company in the high-flow nasal cannula industry and gained its competitive edge.
List of the prominent players in the High Flow Nasal Cannula Market:
The High Flow Nasal Cannula Market is segmented as follows:
By Product Type
By Application
By End User
By Sales Channel
Regional Coverage:
North America
Europe
Asia Pacific
The Middle East & Africa
Latin America
Updated: January 2026 · Formats: PDF, Excel, PPT
The High Flow Nasal Cannula market is driven by several factor such as rapid technological advancements, rising prevalence of COPD, rising tobacco use and many others.
The "Acute Respiratory Failure" had the largest share in the global market for High Flow Nasal Cannula.
The "Single Heated Tube" category dominated the market in 2024.
The key players in the market are Vapotherm Inc., Armstrong Medical Ltd, Salter Labs Inc, ResMed Inc., Teleflex Inc, BD, Smiths Medical, Flexicare Medical Ltd, Teijin Pharma Limited, TNI Medical AG, Fisher & Paykel Healthcare Limited, Hamilton Medical AG, Drägerwerk AG & Co. KGaA, Heka Medicals India Pvt Ltd., GaleMed Corporation, Others.
"North America" is expected to dominate the market over the forecast period.
The global market is projected to grow at a CAGR of 5.4% during the forecast period, 2025-2034.
The High Flow Nasal Cannula Market size was valued at USD 3.7 Billion in 2025.
Author · Sr. Research Analyst
Ayush Kadam is a Senior Market Research Analyst at Custom Market Insights, with over seven years of experience in syndicated and custom market research. He specializes in market sizing, competitive intelligence, industry trends, forecasting, and strategic insights, helping clients turn complex data into actionable business decisions.
Buy individual chapters for $490 each: 9 chapters available, from Executive Summary to Company Profiles.
Get the full report structure, sample pages and data tables in the free sample.
Download free sampleGet the full report structure, sample pages and data tables in the free sample.
Download free sampleGet the full report structure, sample pages and data tables in the free sample.
Download free sample